Permanent Trial Closure: BRC2 and BRC2E

BRC2 (E1505): A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/= 4 cm) – III a non-small cell lung cancer (NSCLC) trial. NCT00324805: Results are available on www.clinicaltrials.gov

BRC2E (CCTG): A prospective economic analysis of NCIC CTG BRC.2/E1505 A Phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/= 4 cm) – III a non-small cell lung cancer (NSCLC) Trial.

For more information on both please visit the members trial page.